Spontaneous immunity against the receptor tyrosine kinase ROR1 in patients with chronic lymphocytic leukemia

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Hojjat Farsangi, Mohammad ^a,b   Jeddi Tehrani, Mahmood ^c   Daneshmanesh, Amir Hossein ^a   Mozaffari, Fariba ^a   Moshfegh, Ali ^a   Hansson, Lotta ^a   Razavi, Seyed Mohsen ^d   Sharifian, Ramazan Ali ^b   Rabbani, Hodjattallah ^c   Österborg, Anders ^a   Mellstedt, Håkan ^a   Shokri, Fazel ^b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 5; PROTEIN ROR1; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ANTIBODY; PEPTIDE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CANCER PROGNOSIS; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPRECIPITATION; LEUKEMIA CELL LINE; LYMPHOCYTE PROLIFERATION; MTT ASSAY; PROTEIN DOMAIN; T LYMPHOCYTE; THYMIDINE INCORPORATION ASSAY; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BLOOD; FEMALE; IMMUNITY; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; PROGNOSIS;

AMINO ACID SEQUENCE; ANTIBODIES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNITY; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-5; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDES; PROGNOSIS; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; T-LYMPHOCYTES;

EID: 84955614428     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142310     Document Type: Article

References (43)

1. Boelens J, Lust S, Vanhoecke B., Offner F. Chronic lymphocytic leukaemia. Anticancer Res. 2009; 29: 605-615. PMID: 19331210
2. Klein U, Tu Y, Stolovitzky G.A., Mattioli M., Cattoretti G, Husson H, et al Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001; 194:1625-1638. PMID: 11733577
3. Rosenwald A, Alizadeh AA, Widhopf G, Simon R., Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001; 194:1639-1647. PMID: 11733578
4. Masiakowski P, Carroll RD A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem. 1992; 267: 26181-26190. PMID: 1334494
5. Plass C, Byrd JC, Raval A, Tanner SM, de la Chapelle A. Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes. Br J Haematol. 2007; 139:744-752. PMID: 17961188
6. Hojjat-Farsangi M., Moshfegh A, Daneshmanesh A.H., Khan AS, Mikaelsson E, Osterborg A, et al The receptor tyrosine kinase ROR1 - an oncofetal antigen fortargeted cancer therapy. Semin Cancer Biol. 2014; 29: 21-31. doi: 10.1016/j.semcancer.2014.07.005 PMID: 25068995
7. Yoda A, Oishi I, Minami Y. Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans. J Recept Signal Transduct Res. 2003; 23:1-15. PMID: 12680586
8. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008; 14: 396-404. doi: 10.1158/1078-0432.CCR-07-1823 PMID: 18223214
9. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat A.A., Ghods R., Ostadkarampour M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer. 2008; 123:1190-1195. doi: 10.1002/ijc.23587 PMID: 18546292
10. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA. 2008; 105: 3047-3052. doi: 10.1073/pnas.0712148105 PMID: 18287027
11. Yu J, Cui B, Widhopf GF II, Chen L, Rassenti L, Wang Z, et al. Preclinical Development Of ROR1 Peptide Based Vaccine With Activity Against Chronic Lymphocytic Leukemia In ROR1 Transgenic Mice. Blood (ASH Annual Meeting Abstracts). 2013; 122: Abstract No: 4174.
12. Hojjat-Farsangi M., Ghaemimanesh F, Daneshmanesh A.H., Bayat AA, Mahmoudian J, Jeddi-Tehrani M, et al. Inhibition of the Receptor Tyrosine Kinase ROR1 byAnti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells. PLoSOne. 2013; 8: e61167. doi: 10.1371/journal.pone.0061167 PMID: 23593420
13. Daneshmanesh AH, Hojjat-Farsangi M, Khan A.S., Jeddi-Tehrani M, Akhondi MM, Bayat A.A., et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia. 2012; 26:1348-1355. doi: 10.1038/leu.2011.362 PMID: 22289919
14. Rezvany MR, Jeddi-Tehrani M, Biberfeld P., Soderlund J, Mellstedt H, Osterborg A., et al. Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern. Br J Haematol. 2001; 115: 263-271. PMID: 11703320
15. Palma M, Hansson L, Choudhury A, Nasman-Glaser B, Eriksson I, Adamson L, et al. Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria. Cancer Immunol Immunother. 2012; 61: 865-879. doi: 10.1007/s00262-011-1149-5 PMID: 22086161
16. Morrison J, Elvin J, Latron F., Gotch F, Moots R, Strominger J.L., et al. Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. Eur J Immunol. 1992; 22: 903-907. PMID: 1372560
17. Zweerink HJ, Gammon MC, Utz U, Sauma S.Y., Harrer T, Hawkins JC, et al. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J Immunol. 1993; 150:1763-1771. PMID: 7679694
18. Abdalla AO, Kokhaei P, Hansson L, Mellstedt H, Osterborg A. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC). Ann Oncol. 2008; 19:1172-1179. doi: 10.1093/annonc/mdn017 PMID: 18272909
19. Hojjat-Farsangi M., Khan AS, Daneshmanesh A.H., Moshfegh A., Sandin A, Mansouri L, et al The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PLoSOne. 2013; 8: e78339. doi: 10.1371/journal.pone.0078339 PMID: 24205204
20. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005; 8:140-174. PMID: 15564720
21. Matsuda T, Nomi M, Ikeya M, Kani S, Oishi I, Terashima T, et al. Expression of the receptortyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech Dev. 2001; 105:153-156. PMID: 11429290
22. Al-Shawi R., Ashton SV, Underwood C, Simons JP Expression of the Ror1 and Ror2 receptortyrosine kinase genes during mouse development. Dev Genes EVol. 2001; 211:161-171. PMID: 11455430
23. Lapalombella R, Andritsos L, Liu Q., May SE, Browning R, Pham LV, et al Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 2010; 115: 2619-2629. doi: 10.1182/blood-2009-09-242438 PMID: 19965642
24. Jadidi-Niaragh F., Ghalamfarsa G, Memarian A, Asgarian-Omran H, Razavi SM, Sarrafnejad A, et al. Downregulation of IL-17-producingTcells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia. Tumour Biol. 2013; 34: 929-940. doi: 10.1007/s13277-012-0628-4 PMID: 23269607
25. Jadidi-Niaragh F., Jeddi-Tehrani M, Ansaripour B, Razavi SM, Sharifian RA, Shokri F. Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia. Med Oncol. 2012; 29: 3561-3569. doi: 10.1007/s12032-012-0262-4 PMID: 22669567
26. Jadidi-Niaragh F., Yousefi M, Memarian A., Hojjat-Farsangi M, Khoshnoodi J, Razavi S.M., et al. Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression. Cancer Invest. 2013; 31:121-131. doi: 10.3109/07357907.2012.756110 PMID: 23286587
27. Scrivener S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003; 44: 383-389. PMID: 12688308
28. Oppezzo P, Dighiero G. "Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia". Blood Cancer J. 2013; 3: e149. doi: 10.1038/bcj.2013.45 PMID: 24056719
29. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N EnglJ Med. 2001; 344: 655-664. PMID: 11228281
30. Baig NA, Taylor RP, Lindorfer M.A., Church AK, Laplant BR, Pavey ES, et al. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk Lymphoma. 2012; 53: 2218-2227. doi: 10.3109/10428194.2012.681657 PMID: 22475085
31. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007; 44: 3823-3837. PMID: 17768100
32. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010; 116: 4532-4541. doi: 10.1182/blood-2010-05-283309 PMID: 20702778
33. Finn OJ. Cancer immunology. N Engl J Med. 2008; 358: 2704-2715. doi: 10.1056/NEJMra072739 PMID: 18565863
34. Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancertreatment. Biochim Biophys Acta. 2007; 1776:108-123. PMID: 17720322
35. Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, et al. Cellular immune responses against CT7 (MAGE-C1)and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun. 2010; 10: 4. PMID: 20108890
36. Jin S, Wang Y, Zhang Y, Zhang HZ, Wang SJ, Tang JQ, et al. Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity. Cancer Sci. 2008; 99:1670-1678. doi: 10.1111/j.1349-7006.2008.00860.x PMID: 18754882
37. Gnjatic S, Nishikawa H, Jungbluth AA, Gure A.O., Ritter G., Jager E, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006; 95:1-30. PMID: 16860654
38. van Rhee F., Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005; 105: 3939-3944. PMID: 15671442
39. Jager D, Jager E, Knuth A. Vaccination for malignant melanoma: recent developments. Oncology. 2001; 60:1-7. PMID: 11150901
40. Adam JK, Odhav B, Bhoola KD. Immune responses in cancer. Pharmacol Ther. 2003; 99:113-132. PMID: 12804702
41. von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers. 2000; 15: 343-356. PMID: 11192832
42. Widhopf GF 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z, et al. ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice. Proc Natl Acad Sci USA. 2014; 111: 793-798. doi: 10.1073/pnas.1308374111 PMID: 24379361
43. Daneshmanesh AH, Hojjat-Farsangi M, Moshfegh A., Khan AS, Mikaelsson E, Osterborg A, et al The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies. Br J Haematol. 2015; 169: 455-458. doi: 10.1111/bjh.13228 PMID: 25407287